Oncology Associates Of Oregon, Pc

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials
• Gastric and oesophageal cancer2 trials
• Bladder cancer1 trial
• Liver and biliary tract cancer1 trial
• Pancreatic cancer1 trial

Phase

• Phase 34 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Active, not recruiting2 trials
• Completed2 trials
• Recruiting2 trials

Lead sponsor

• Bristol-Myers Squibb3 trials
• Amgen1 trial
• Boehringer Ingelheim1 trial
• Revolution Medicines, Inc.1 trial

Running trials

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

  Contact: Bo Wang, Site 0895

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source

  Contact: Marc Uemura, Site 0432

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· Phase 3· Revolution Medicines, Inc.· Source

  Contact: Revolution Medicines Study Director

• Active, not recruiting

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· Phase 3· Amgen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

  NCT05512377· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

  NCT03143153· Phase 3· Bristol-Myers Squibb· Source